Literature DB >> 16228269

Efficacy of toltrazuril as a metaphylactic and therapeutic treatment of coccidiosis in first-year grazing calves.

C Epe1, G von Samson-Himmelstjerna2, N Wirtherle2, V von der Heyden2, C Welz2, J Beening3, I Radeloff3, K Hellmann4, T Schnieder2, K Krieger5.   

Abstract

A multicentric, placebo-controlled, randomised, blinded and blocked field study was conducted to evaluate the efficacy and safety of toltrazuril (Baycox, Bayer AG, Leverkusen, Germany) in the treatment of coccidiosis in first-year grazing calves naturally infected with Eimeria spp. Three-hundred and thirty-one calves were enrolled in the study and allocated to one of two treatments at a ratio of 1:1. One hundred and sixty-seven animals were treated once orally with 15 mg/kg toltrazuril, and 164 animals served as placebo-treated controls. Two treatment regimes were compared, a metaphylactic (treatment on the day, or 1 day after, turn out) and a therapeutic treatment (4 or 7 days after turn out). During an observation period of 14 days after treatment the animals were clinically examined for diarrhoea and faecal samples were regularly assessed for Eimeria oocysts. Other possible causes of diarrhoea were excluded on the basis of microbiological and virological examination. Animals were predominantly infected with Eimeria alabamensis. Number of days with diarrhoea in animals treated with toltrazuril was significantly lower compared to the placebo-treated group (therapeutic treatment: P=0.0024; metaphylactic treatment: P<0.0001). Furthermore, the number of animals with diarrhoea during the observation period for a minimum of at least 3 days, the number of animals positive for Eimeria oocysts, and the number of animals with both diarrhoea for a period of at least 3 days and positive for Eimeria oocysts, were significantly lower (P<0.01), in the toltrazuril- compared to the placebo-treated animals. Body weight in the toltrazuril-treated animals significantly exceeded that of the placebo-treated animals at the end of the observation period. Mean difference in body weight was higher in the metaphylactic (+7.3 kg) compared to the therapeutic treatment group (+3.4 kg). No adverse reactions were observed. The results indicate that toltrazuril is highly efficacious and safe in the metaphylactic and therapeutic treatment of coccidiosis caused by E. alabamensis in first-year grazing calves.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228269      PMCID: PMC7087692          DOI: 10.1007/s00436-005-1456-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  6 in total

1.  Long-term efficacy of toltrazuril in naïve calves prophylactically treated and experimentally infected with Eimeria spp.

Authors:  Dina María Beltrán Zapa; Luiz Fellipe Monteiro Couto; Luciana Maffini Heller; Lorena Lopes Ferreira; Hariye Victória Iuasse; Raphaela Barbosa Naves; Artur Siqueira Nunes Trindade; Lídia Mendes De Aquino; Vando Edesio Soares; Welber Daniel Zanetti Lopes
Journal:  Parasitol Res       Date:  2022-07-27       Impact factor: 2.383

2.  Influence of a metaphylactic treatment with Baycox(®) Bovis on the reproductive performances of Fresian heifers: a preliminary study.

Authors:  Fabrizia Veronesi; Lucio Nisoli; Manuela Diaferia; Roberto Falcini; Emanuele Ficola; Daniela Piergili Fioretti
Journal:  Parasitol Res       Date:  2013-03-16       Impact factor: 2.289

3.  Comparative efficacy of diclazuril (Vecoxan®) and toltrazuril (Baycox bovis®) against natural infections of Eimeria bovis and Eimeria zuernii in French calves.

Authors:  P Philippe; J P Alzieu; M A Taylor; Ph Dorchies
Journal:  Vet Parasitol       Date:  2014-12-15       Impact factor: 2.738

4.  Bovine Eimeria species in Austria.

Authors:  H Koutny; A Joachim; A Tichy; W Baumgartner
Journal:  Parasitol Res       Date:  2011-12-14       Impact factor: 2.289

5.  The influence of storage time on ponazuril concentrations in feline plasma.

Authors:  Sherry Cox; Lainey Harvill; Sarah Singleton; Joan B Bergman; Becky DeBolt
Journal:  PeerJ       Date:  2021-11-26       Impact factor: 2.984

6.  Pharmacokinetics of orally administered single-dose ponazuril in cats.

Authors:  Catherine Burlison; Sherry Cox; Joseph Smith; Jennifer Stokes; Jacqueline C Whittemore; Becky DeBolt
Journal:  J Vet Pharmacol Ther       Date:  2022-03-20       Impact factor: 1.567

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.